Pharmacologic C5aR1 antagonism in the Arctic mouse model of Alzheimer's disease modifies microglial polarization and astrocyte signaling
SC and SN RNA-seq reveal that pharmacologic inhibition of C5aR1 both suppresses disease enhancing processes and promotes disease mitigating pathways in an AD mouse model. Overall design: The Arctic model of Alzheimer's disease and wildtype mice were treated with a C5aR1 antagonist (PMX205) or not for 12 weeks.  Hippocampi were dissect and processed for single cell and single nucleus RNA-sequencing